These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 23587333)

  • 1. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
    Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
    J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood.
    De Puysseleyr LP; Ebo DG; Elst J; Faber MA; Poorten MV; Van Gasse AL; Bridts CH; Mertens C; Van Houdt M; Hagendorens MM; Verlinden A; Vermeulen K; Maes MB; Berneman ZN; Sabato V
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3176-3187.e3. PubMed ID: 33975032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
    Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
    Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.
    Garcia-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Teodosio C; Sanchez-Muñoz L; Muñiz C; Muñoz-Gonzalez JI; Mayado A; Matito A; Caldas C; Morgado JM; Escribano L; Orfao A
    Blood; 2016 Feb; 127(6):761-8. PubMed ID: 26622064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
    Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
    Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CD34
    Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
    Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
    Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
    Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
    Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
    Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
    Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
    Kristensen T; Vestergaard H; Møller MB
    J Mol Diagn; 2011 Mar; 13(2):180-8. PubMed ID: 21354053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Prognostic Impact of the
    Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
    Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
    Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.